The Technical Analyst
Vir Biotechnology Inc [VIR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vir Biotechnology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.11% $8.04
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 092.19 mill |
| EPS: | -4.59 |
| P/E: | -1.750 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 135.84 mill |
| Avg Daily Volume: | 1.058 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.750 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.750 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 7.59 - 8.51 ( +/- 5.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | De Backer Marianne | Sell | 72 995 | Common Stock |
| 2024-04-01 | Hanly Ann M. | Sell | 2 711 | Common Stock |
| 2024-03-27 | Lee Sung | Sell | 6 008 | Common Stock |
| 2024-02-22 | Hanly Ann M. | Buy | 32 500 | Common Stock |
| 2024-02-22 | Hanly Ann M. | Sell | 12 296 | Common Stock |
| INSIDER POWER |
|---|
| -10.20 |
| Last 98 transactions |
| Buy: 8 177 990 | Sell: 9 772 896 |
Forecast:
16:00 - $8.04
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.04
Forecast 2: 16:00 - $8.04
Forecast 3: 16:00 - $8.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.04 (-1.11% ) |
| Volume | 0.738 mill |
| Avg. Vol. | 1.058 mill |
| % of Avg. Vol | 69.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VIR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $9.17 | N/A | Active |
|---|
VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Latest Press Releases
2024-04-18 08:00:00 - Press Release
Vir Biotechnology Announces Nomination Of Norbert Bischofberger, Ph.d. And Ramy Farid, Ph.d.
San francisco--(business wire)--vir biotechnology, inc. (“vir” or “the company”, nasdaq: vir) today announced the nomination of norbert bischofberger, ph.d. and ramy farid, ph.d. to its board of directors (the “board”) at its upcoming annual meeting of stockholders on may 29, 2024 (the “annual meeting”). if elected, each of drs. bischofberger and farid will join the board on such date. the nomination of the two new independent directors demonstrates vir's commitment to ongoing board refreshment.
2024-04-11 16:30:00 - Press Release
Vir Biotechnology To Provide Business Update And Report First Quarter 2024 Financial Results On May 2, 2024
San francisco--(business wire)--vir biotechnology, inc. (nasdaq: vir) today announced the company will provide a corporate update and report financial results for the first quarter ended march 31, 2024, on may 2, 2024. the company will host a conference call at 1:30 p.m. pacific time / 4:30 p.m. eastern time on may 2, 2024. the corporate update and financial results will be provided via a press release after market close and will be accessible under press releases in the investors section of th.
2024-02-23 08:05:00 - Press Release
Vir Biotechnology To Participate In Upcoming Investor Healthcare Conferences
San francisco--(business wire)---- $vir--vir biotechnology to participate in upcoming march investor healthcare conferences.
2024-02-22 16:05:00 - Press Release
Vir Biotechnology Provides Corporate Update And Reports Fourth Quarter And Full Year 2023 Financial Results
San francisco--(business wire)--vir biotechnology, inc. (nasdaq: vir) today provided a corporate update and reported financial results for the fourth quarter and full year ended december 31, 2023. “vir is poised to have a transformational year, with catalysts expected in the second and fourth quarters, which build off last year's clinical trial progress in our chronic hepatitis delta and b programs. we believe these data readouts, notably the solstice delta update in the second quarter, hold tr.
2024-02-01 16:05:00 - Press Release
Vir Biotechnology To Provide Business Update And Report Fourth Quarter 2023 Financial Results On February 22, 2024
San francisco--(business wire)---- $vir--vir biotechnology to provide business update and report fourth quarter 2023 financial results on february 22, 2024.
Latest News
2024-04-24 13:01:26 - Zacks Investment Research
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology (VIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-11 16:30:00 - Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of th.
2024-03-19 14:58:39 - InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
2024-02-27 23:56:21 - Seeking Alpha
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Vir Biotechnology is developing treatments for Hepatitis B, Hepatitis Delta, HIV, and COVID, among others.
2024-02-23 10:56:04 - Zacks Investment Research
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-22 18:51:32 - Zacks Investment Research
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
2024-01-31 13:16:05 - Zacks Investment Research
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
2024-01-15 12:47:33 - Zacks Investment Research
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
2023-12-06 16:05:00 - Business Wire
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir Biotechnology Vi.
2023-11-30 06:10:00 - InvestorPlace
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the potential giants of tomorrow, starting as small-caps and gradually ascending to large or even mega-cap status through consistent earnings expansion.